OKYO Pharma Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OKYO research report →
Range $5 – $5
Price Chart
About the company
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain.
- CEO
- Robert J. Dempsey
- IPO
- 2022
- Employees
- 5
- HQ
- London, GL, GB
Get TickerSpark's AI analysis on OKYO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $56.02M
- P/E
- -6.11
- Fwd P/E
- 7.30
- PEG
- 0.05
- P/S
- 0.00
- P/B
- 4.43
- EV/EBITDA
- -4.50
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -200.67%
- ROIC
- -74.59%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-6,690,509-260942.1%
- Op Income
- $-8,499,553
- Net Income
- $-8,949,657-90.2%
- EPS
- $-0.24-100.0%
- OCF Growth
- -227.8%
- FCF Growth
- -227.9%
- 52W High
- $3.20
- 52W Low
- $1.26
- 50D MA
- $1.49
- 200D MA
- $1.69
- Beta
- 0.04
- RSI (14)
- 54
- Avg Volume
- 106.25K
No earnings-call transcripts are available for OKYO yet.
- Free Float
- 53.6%
- Shares Outstanding
- 38.37M
- Float Shares
- 20.55M
of shares held by institutions
1 13F filers
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 21, 26 | BRANCACCIO JOHN P | buy | 5,000 |
| Jul 22, 26 | Dempsey Robert John | buy | 15,000 |
| Jul 21, 26 | JACOB GARY S | buy | 3,500 |
| Jul 21, 26 | CERRONE GABRIELE M | buy | 22,500 |
| Jul 20, 26 | CERRONE GABRIELE M | buy | 25,000 |
| Jul 21, 26 | Mantelli Flavio | buy | 20,000 |
| Jul 27, 26 | Patil Rajkumar V. | buy | 3,363 |
| Jul 27, 26 | Patil Rajkumar V. | other | 3,363 |
| Mar 18, 26 | Patil Rajkumar V. | other | 0 |
| Mar 14, 27 | Patil Rajkumar V. | other | 59,616 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OKYO coverage
Recent articles, reports, and earnings notes.
No research on OKYO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OKYO report →OKYO Pharma enrolls first patients in Phase 3 trial of neuropathic corneal pain drug
proactiveinvestors.com · Oct 6
OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain
globenewswire.com · Oct 6
OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences
globenewswire.com · Sep 29
OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026
globenewswire.com · Sep 9
OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference
globenewswire.com · Sep 8
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
globenewswire.com · Jul 28
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
globenewswire.com · Jul 27
OKYO Pharma Announces Purchase of Shares by Director
globenewswire.com · Jul 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.